29June

Rybelsus® approved in Japan for the treatment of type 2 diabetes ... Read more

18June

Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination ... Read more

12June

Semaglutide 2.4 mg shows superior weight loss versus placebo in the phase 3 tria ... Read more

11June

Novo Nordisk to acquire Corvidia Therapeutics and expand presence in cardiovascu ... Read more

29June

Novo Nordisk A/S – Share repurchase programme ... Read more

29June

Rybelsus® approved in Japan for the treatment of type 2 diabetes ... Read more

22June

Novo Nordisk A/S – Share repurchase programme ... Read more

18June

Novo Nordisk successfully completes AM833 phase 2 trial and phase 1 combination ... Read more

06August

Financial statement for the first six months of 2020,

01October

Silent period,

30October

Financial statement for the first nine months of 2020,

08March

Commerzbank Sector Conference , Frankfurt

 

 

 

Investors

Share information
 

SHARE Magazine


Get the latest SHARE Magazine

News for you as an investor

 

Corporate reporting

Private shareholders


Shareholder tools and systems for private investors

 

Investor materials

Contact Investor Relations

Sign-up: Company announcements


Sign up and receive our company announcements

 

Financial results and events overview